The Latest Breaking News from Moderna

Moderna's (NASDAQ:MRNA) short percent of float has fallen 4.65% since its last report. The company recently reported that it has 14.76 million shares sold short, which is 4.31% of all regular shares that are available for trading.

Moderna has created a new type of jab, codenamed 214, which is said to be more effective than previous vaccines, according to reports

The jab engineered to tackle the new variants causing a summer wave is expected to be approved for use in the UK

Tweaked vaccines to tackle Omicron are in trials as JCVI finalises advice for vulnerable groups

The jab, known as “214”, is bivalent, which means it helps build immunity to both the original Wuhan strain and the Omicron variants

The case is growing to tweak the jabs to target more tranmissible Omicron variants, experts say

A whale with a lot of money to spend has taken a noticeably bullish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 19 strange trades.

With immunity waning and the super-contagious omicron family of variants getting better at dodging protection, the Food and Drug Administration decided boosters intended for fall needed an update.

U.S. regulators are telling COVID-19 vaccine makers to tweak any booster doses intended for fall so they protect against the newest omicron relatives

The FDA will have to decide the exact recipe. But expect a combination shot that adds protection against omicron or some of its newer relatives to the original vaccine.

The Food and Drug Administration’s panel of independent vaccine experts recently voted 19 to 2 to recommend a new batch of COVID-19 booster shots targeting the omicron variant this fall. The news, announced Tuesday, June 28, could have a big impact on the share prices of vaccine makers.